OliX Pharmaceuticals
Manufacturing · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1014 Ace Gwanggyo Tower 17, Suwon-si, Gy...Phone Number
+82 317798400Website
www.olixpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About OliX Pharmaceuticals
OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company's core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.Explore more
OliX Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OliX Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if OliX Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
OliX Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at OliX Pharmaceuticals
Click to see if OliX Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on OliX Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when OliX Pharmaceuticals launches new products
Check out if OliX Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once OliX Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
OliX Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OliX Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OliX Pharmaceuticals.
OliX Pharmaceuticals financials insights
Gather financial insights about OliX Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$37.2M
2022
Share Placement
$45M
OliX Pharmaceuticals Tech Stack
Most Recent Scoops
Partnership
Partnership, Research & Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Project
Product Development, Research & Development, Product Management
Funding
Open Position
Funding
OliX Pharmaceuticals News & Media
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
SEONGNAM, South Korea--(BUSINESS WIRE)-- #CardiometabolicIndications--OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s OLX75016.OliX Pharmaceuticals Commences Patient Dosing in Phase 1 Clinical Trial of OLX75016 for MASH
SUWON, South Korea--(BUSINESS WIRE)-- #GIP--OliX Pharmaceuticals initiated patient dosing in the Phase 1 clinical trial of OLX75016 for MASHOliX Pharmaceuticals Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug
SUWON, South Korea--(BUSINESS WIRE)-- #AMD--OliX Pharmaceuticals, Inc. received approval from the HREC to conduct a Phase 1 clinical trial of drug candidate OLX75016OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration
SUWON, South Korea--(BUSINESS WIRE)-- #AMD--OliX announced positive results from a Phase 1 study of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding OliX Pharmaceuticals
Sign Up For FreeTo access detailed company insights
OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company's core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (... Read More
